48,830
edits
m (→Prostate gland) |
(→One organ vs. another: more) |
||
Line 170: | Line 170: | ||
*ICC: CK19 (92.5%), MUC-1 (73.8%) +ve. | *ICC: CK19 (92.5%), MUC-1 (73.8%) +ve. | ||
*HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve. | *HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve. | ||
===Prostate vs. bladder=== | |||
Prostate adenocarcinoma vs. urothelial carcinoma: | |||
*Prostate:PSA +ve, PSAP +ve, AR +ve, CK7 -ve, CK20 -ve. | |||
*Urothelial carcinoma: CK7 +ve, CK20 +ve, PSA -ve, PSAP -ve, AR -ve. | |||
==Lymphomas== | ==Lymphomas== |
edits